Bengaluru: Alembic Pharmaceuticals Limited reported its consolidated financial results for the third quarter ended 31st December, 2024.
Financial Highlights
- Net Sales increased by 4% to Rs.1693 Crores.
- EBITDA up 1% to Rs. 271 Crores
- EBITDA Margin at 16% of Sales
- Net Profit at Rs.138 Crores
Mr. Shaunak Amin, MD, Alembic Pharmaceuticals Limited said. “In the current quarter, we faced market headwinds in the acute segment. However, other key therapies in our specialty business continued to outpace the market growth. To strengthen field force efficiency, we have enhanced Automation and AI, to upscale execution. This Transition has partly impacted quarter growth. We are confident to show a robust growth trajectory going forward. The US Business posted significant volume growth and the Ex-US markets continued to expand steadily. API Business is still under significant pricing pressure.”
Operational Highlights
India Branded Business
India Branded Business grew 3% to Rs. 614 crores for the quarter.
Animal Health business grew 22% for the quarter with basket of strong brands driving outperformance.
Specialty therapies recorded growth of 6%.
3 launches during the quarter. New launches continue to do well along with promising future launches across key segments.
International Business
US Generics grew 10% to Rs. 521 Crores for the quarter.
2 Launches in the US market during the quarter.
Ex-US International Generics grew 10% to Rs. 299 Crores for the quarter.
7 ANDA approvals received during the quarter, 219 Cumulative ANDA approvals.
API Business
API business at Rs. 259 Crores for the quarter.
The summary of Total Revenue is as under:
(Rs in Crores)
| Particulars | Q3 FY25 | Q3 FY24 | % Change | 9M FY25 | 9M FY24 | % Change |
| Formulation | ||||||
| India | 614 | 596 | 3% | 1795 | 1697 | 6% |
| USA Ex- US | 521 299 | 474 272 | 10% 10% | 1449 868 | 1308 790 | 11% 10% |
| API | 259 | 289 | (10%) | 791 | 916 | (14%) |
| Total | 1693 | 1631 | 4% | 4902 | 4712 | 4% |
